MA41643B1 - PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR - Google Patents

PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR

Info

Publication number
MA41643B1
MA41643B1 MA41643A MA41643A MA41643B1 MA 41643 B1 MA41643 B1 MA 41643B1 MA 41643 A MA41643 A MA 41643A MA 41643 A MA41643 A MA 41643A MA 41643 B1 MA41643 B1 MA 41643B1
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
pharmaceutical formulations
bruton
kinase inhibitor
conditions
Prior art date
Application number
MA41643A
Other languages
French (fr)
Other versions
MA41643A (en
Inventor
Robert Kuehl
Harisha Atluri
Ching Chong
Heow Tan
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Priority claimed from PCT/US2016/020467 external-priority patent/WO2016141068A1/en
Publication of MA41643A publication Critical patent/MA41643A/en
Publication of MA41643B1 publication Critical patent/MA41643B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne des formulations pharmaceutiques d'un inhibiteur de la tyrosine kinase de bruton (btk), le 1-((r)-3-(4-amino-3-(4-phénoxyphényl)-1h-pyrazolo [3,4-d] pyrimidin-1-yl) pipéridin-1-yl) prop-2-én-1-one. L'invention concerne des procédés d'utilisation de l'inhibiteur de btk, seul ou en combinaison avec d'autres agents thérapeutiques, pour le traitement de maladies ou de pathologies auto-immunes, de maladies ou de pathologies hétéro-immunes, du cancer, y compris du lymphome, et de maladies ou de pathologies inflammatoires.The invention relates to pharmaceutical formulations of a bruton tyrosine kinase (btk) inhibitor, 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one. The invention relates to methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer , including lymphoma, and inflammatory diseases or pathologies.

MA41643A 2015-03-03 2016-03-02 PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR MA41643B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127717P 2015-03-03 2015-03-03
PCT/US2016/020467 WO2016141068A1 (en) 2015-03-03 2016-03-02 Pharmaceutical formulations of bruton's tyrosine kinase inhibtor

Publications (2)

Publication Number Publication Date
MA41643A MA41643A (en) 2018-01-09
MA41643B1 true MA41643B1 (en) 2024-02-29

Family

ID=59254075

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41643A MA41643B1 (en) 2015-03-03 2016-03-02 PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR

Country Status (2)

Country Link
AR (1) AR103832A1 (en)
MA (1) MA41643B1 (en)

Also Published As

Publication number Publication date
AR103832A1 (en) 2017-06-07
MA41643A (en) 2018-01-09

Similar Documents

Publication Publication Date Title
MA41654B2 (en) Crystal forms of a bruton tyrosine kinase inhibitor
MX2021015405A (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibtor.
PH12020552065A1 (en) Ibrutinib combination therapy
MX2017001671A (en) Novel formulations of a bruton's tyrosine kinase inhibitor.
MX2017012411A (en) Co-crystals of a bruton's tyrosine kinase inhibitor.
TN2015000168A1 (en) INHIBITORS OF BRUTON TYROSINE KINASE
MA38961A1 (en) 3-phenyl-1h-pyrazolo [3,4-d] pyrimidin-4-ylamine compounds substituted for the crude tyrosine kinase inhibitors used to treat, for example, autoimmune, respiratory and inflammatory diseases, cancer, mastocytosis and osteoporosis
MA38183A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MX2017012430A (en) Solvated forms of a bruton's tyrosine kinase inhibitor.
PH12015502053A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
MX2019008815A (en) Synthesis of a bruton's tyrosine kinase inhibitor.
EA201690746A1 (en) TREATMENT WITH THE USE OF BLUTON AND IMMUNOTHERAPY THYROZINKINASE INHIBITORS
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MA41643B1 (en) PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR